I-Mab Biopharma, a Chinese-clinical stage biopharmaceutical company, has filed for an up to US$100 million IPO of American Depository Shares (ADS) on the Nasdaq on Tuesday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?